Pharmaxis Ltd (AU:SNT) has released an update.
Syntara Limited has announced its CEO, Mr Gary Phillips, will present at the ‘Hidden Gems in Life Sciences’ Webinar, inviting shareholders and interested parties to the virtual event scheduled for June 13. The presentation will focus on the company’s advancements, including their lead drug candidate SNT-5505 for myelofibrosis, which has received FDA Orphan Drug Designation. Additionally, Syntara continues to develop treatments for a range of fibrotic and inflammatory diseases and earns royalties from two respiratory products.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.
